- Home
- TTGT vs VOR Comparison
TTGT vs VOR Comparison
Compare TTGT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TTGT | VOR |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.1M | 345.1M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TTGT | VOR |
|---|---|---|
| Price | $4.80 | $13.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $11.25 | ★ $64.78 |
| AVG Volume (30 Days) | 431.3K | ★ 676.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $74.33 | N/A |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $0.13 |
| 52 Week High | $15.54 | $49.95 |
Technical Indicators
Market Signals| Indicator | TTGT | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 31.69 | 48.54 |
| Support Level | $5.03 | $12.80 |
| Resistance Level | $5.09 | $13.74 |
| Average True Range (ATR) | 0.17 | 1.00 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 8.62 | 56.27 |
Price Performance
Historical ComparisonAbout TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.